LB-100

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

LB-100 is an experimental drug currently being studied in clinical trials for metastatic colorectal cancer. It is being investigated in combination with atezolizumab (Tecentriq), a type of immunotherapy. The trials are specifically looking at patients whose tumors are microsatellite stable (MSS), meaning they are less likely to respond to standard immunotherapy alone. The goal of these early-phase trials (Phase 1) is to determine the safety and tolerability of LB-100 when given with atezolizumab, find the best dose of LB-100, and get a preliminary look at whether the combination shows any signs of effectiveness (anti-tumor activity). LB-100 is given intravenously every three weeks. This drug is not yet approved for treating colorectal cancer.

Mechanism of Action

LB-100 is being studied as a PP2A inhibitor. PP2A is a protein phosphatase involved in many cellular processes, including cell growth and survival. By inhibiting PP2A, LB-100 may disrupt these processes in cancer cells, potentially leading to their death or reduced growth. The specific way LB-100 affects cancer cells and its precise molecular target are still being investigated in clinical trials.

Side Effects

As LB-100 is an experimental drug in early-phase clinical trials The full range of potential side effects is still being evaluated. The trials are primarily focused on assessing safety and tolerability. Participants in the trials will be closely monitored for any adverse events. Specific side effects related to LB-100 or the combination with atezolizumab are not yet fully known but will be reported as the trials progress. Common side effects of atezolizumab include fatigue Itching Nausea Loss of appetite Diarrhea And cough.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06012734 Phase 1
Recruiting
LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients
Netherlands

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.